LncRNA Information
ID EL1051 Name PCA3 Aliases DD3; NCRNA00019; PCAT3
Species Homo sapiens Chromosome 9 Start site 76764436
End site 76787569 Chain plus Exon NO. 4
Assembly Ensembl Release 89 Class antisense NCBI accession NR_132312, NR_015342, NR_132313
Ensembl ENSG00000225937 Sequence


Disease
Disease Method Sample Expression pattern Dysfunction type Description PMID Source
prostate cancer microarray, RNA-seq, qPCR, Northern bolt, knockdown etc. prostate cancer tissue, cell lines (LNCaP, CWR22Rv1, PC3 etc.) up-regulated N/A Interestingly, nine out of these thirteen known cancer-related lncRNA showed significantly differential expression between tumor and normal prostate samples. Several lncRNA such as NEAT1, DANCR, HOTTIP, PRINS, and EGOT that have established functions in forming nuclear speckles, in development or in autoimmune disease, but were not previously known to be related to cancer, showed differential expression between tumor and normal prostate samples, suggesting their potential function in prostate cancer. 23728290 Lnc2Cancer
prostate cancer N/A N/A N/A expression Measurement of lncRNA PCA3 in patient urine samples has been shown to allow more sensitive and specific diagnosis of prostate cancer than the widely used marker prostate-specific antigen (PSA). 15245811 LncRNADisease
prostate cancer N/A N/A N/A expression The PCA3 assay is insensitive to pre-analytical factors, performs well analytically and correctly classifies a high percent of subjects with known prostate cancer status across research sites. 18054202 LncRNADisease
prostate cancer N/A N/A N/A expression The probability of a positive repeat biopsy increases with rising PCA3 scores. The PCA3 score was superior to %fPSA for predicting repeat prostate biopsy outcome and may be indicative of clinical stage and significance of pCa. 18602209 LncRNADisease
prostate cancer N/A N/A N/A expression Patients with a positive biopsy showed significantly higher PCA3 values. 20424427 LncRNADisease
prostate cancer N/A N/A N/A expression PCA3 scores were significantly lower in low-volume disease and insignificant PCa. Higher PCA3 scores were associated with aggressive disease. 20980098 LncRNADisease
prostate cancer N/A N/A N/A expression Diagnostic marker 24373479 LncRNADisease
prostate cancer N/A N/A N/A N/A PCGEM1, PCA3 (prostate cancer antigen 3, known also as DD3, differential display code 3) and PCNCR1 (prostate cancer ncRNA 2) are involved in prostate cancer, while HULC (highly up-regulated in liver cancer) is involved with liver cancer. 24667321 LncRNADisease
prostate cancer Northern blot etc. prostate cancer tissue up-regulated expression PCA3 is a highly prostate cancer-specific gene. 14607216 LncRNADisease Lnc2Cancer
prostate cancer PROGENSA PCA3 assay etc. blood, urine up-regulated expression A PCA3 score threshold of 20 may have the highest utility for selecting men with clinically insignificant prostate cancer in whom active surveillance may be appropriate; a PCA3 score threshold of 50 may be used to identify men at high risk of harbouring significant prostate cancer who are candidates for RP. 21883822 LncRNADisease Lnc2Cancer
prostate cancer qPCR etc. prostate cancer tissue up-regulated expression Upregulation of two new PCA3 isoforms in PCa tissues improves discrimination between PCa and BPH. 19319183 LncRNADisease Lnc2Cancer
prostate cancer qPCR etc. prostate cancer tissue up-regulated expression PCA3 mRNA is prostate cancer specific and shows increased expression in prostate cancer. 20114043 LncRNADisease Lnc2Cancer
prostate cancer qPCR etc. prostate cancer tissue up-regulated expression It was found that the levels of the mRNA expression of DD3(PCA3) were significantly higher (p<0.045) in patients with PCa than in patients with benign prostatic hyperplasia. 20332487 LncRNADisease Lnc2Cancer
prostate cancer qPCR etc. blood differential expression mutation The presence of the (TAAA)n short tandem repeat polymorphisms in the PCA3 promoter region may be a risk factor for prostate cancer in the Chinese population. 21655300 LncRNADisease Lnc2Cancer
prostate cancer qPCR, in vitro knockdown etc. cell lines (LNCaP, PC3, RWPE-1, PrEC etc.) up-regulated N/A PCA3 is a non-coding RNA (ncRNA) that is highly expressed in prostate cancer (PCa) cells, LNCaP siPCA3-transfected cells significantly inhibited cell growth and viability, and increased the proportion of cells in the sub G0/G1 phase of the cell cycle and the percentage of pyknotic nuclei, compared to those transfected with scramble siRNA (siSCr)-transfected cells. Our findings suggest that the ncRNA PCA3 is involved in the control of PCa cell survival, in part through modulating AR signaling, which may raise new possibilities of using PCA3 knockdown as an additional therapeutic strategy for PCa control. 23130941 Lnc2Cancer
prostate cancer qPCR, Northern blot etc. BPH, prostatic tumor tissue up-regulated expression PCA3 is one of the most prostate cancer-specific genes yet described, and this makes DD3 a promising marker for the early diagnosis of prostate cancer and provides a powerful tool for the development of new treatment strategies for prostate cancer patients. 10606244 LncRNADisease Lnc2Cancer
prostate cancer qPCR, Northern bolt etc. prostate cancer tissue, cell lines (LNCap-AD, 22Rv1, PC-3, DU145, C4-2 etc.) up-regulated N/A qPCR was used to assess the PCA3 and MALAT-1 expression levels in an additional set of 10 pairs of PCa and adjacent normal tissues. Comparing the PCA3 and MALAT-1 expression levels in the 10 paired tissue samples revealed that PCA3 and MALAT-1 were highly expressed in most of the PCa tissues. Plasma lncRNAs probably exist in the form of fragments in a stable form. MD-miniRNA enters cell culture medium at measurable levels, and MD-miniRNA derived from human PCa xenografts actually enters the circulation in vivo and can be measured to distinguish xenografted mice from controls. 23726266 Lnc2Cancer
cancer qRT-PCR LNCaP cell up-regulated N/A PCA3 silencing modulates the expression of key cancer-related genes 26960690
prostate cancer RNA-seq, qPCR etc. prostate cancer tissue up-regulated N/A Consistent with the RNA-seq results, PCA3, FR0348383 and MALAT1 overexpression was found in 80% (32/40), 72.5% (29/40), and 82.5% (33/40) of the prostate cancers respectively, whereas decreased FR0257520 expression was found in 82.5% (33/40) of the prostate cancers. 22349460 Lnc2Cancer
prostate cancer Sequencing etc. prostate cancer tissue, blood(leukocytes) up-regulated N/A By PCR-based cloning and sequencing in paired peripheral blood leukocytes and prostate tissues,5 PCA3 TAAA STR polymorphisms and 8 genotypes were found in both peripheral blood leukocytes and prostate tissues, the carriers with more TAAA repeats were associated with increased risk for PCa than individuals having less TAAA repeats 25445501 LncRNADisease Lnc2Cancer
 


Interaction
Interaction target Level of interaction Type of interaction Description PMID Source
AR cofactors and EMT markers RNA-DNA regulation PCA3 silencing modulates the expression of key cancer-related genes, including those coding for AR cofactors and EMT markers. 26960690